Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价XZ126在既往治疗失败的实体瘤患者的安全性、耐受性、药代动力学特征及初步有效性的I期临床研究
[Translation] A Phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of XZ126 in patients with solid tumors who have failed prior treatment.
主要研究目的:
评价XZ126在既往治疗失败的实体瘤患者中的安全性和耐受性;
评估XZ126在既往治疗失败的实体瘤患者中的剂量限制性毒性(DLT),确定最大耐受剂量(MTD)和/或Ⅱ期推荐剂量(RP2D)。
次要研究目的:
评价XZ126在既往治疗失败的实体瘤患者中的药代动力学(PK)特征;
评价XZ126在既往治疗失败的实体瘤患者中的初步有效性;
评价XZ126与原研Jevtana®(卡巴他赛注射液)在既往治疗失败的实体瘤患者中的PK、耐受性及疗效等方面的差异。
[Translation] Primary Study Objectives:
To evaluate the safety and tolerability of XZ126 in patients with previously untreated solid tumors;
To assess the dose-limiting toxicities (DLT) of XZ126 in patients with previously untreated solid tumors, and to determine the maximum tolerated dose (MTD) and/or the recommended dose for Phase II (RP2D).
Secondary Study Objectives:
To evaluate the pharmacokinetic (PK) characteristics of XZ126 in patients with previously untreated solid tumors;
To evaluate the preliminary efficacy of XZ126 in patients with previously untreated solid tumors;
To evaluate the differences in PK, tolerability, and efficacy between XZ126 and the original Jevtana® (cabatataxel injection) in patients with previously untreated solid tumors.
评价XZ120在恶性肿瘤患者中的安全性、耐受性、药代动力学特征及初步有效性的Ⅰ期临床研究
[Translation] Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of XZ120 in patients with malignant tumors
评价XZ120治疗恶性肿瘤患者的安全性、耐受性、药代动力学特征及初步有效性。
[Translation] To evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of XZ120 in the treatment of patients with malignant tumors.
SPH3127片治疗轻中度溃疡性结肠炎的有效性、安全性评价以及剂量探索的多中心、随机、双盲、安慰剂平行对照的II期临床研究
[Translation] A multicenter, randomized, double-blind, placebo-controlled phase II clinical study on the efficacy, safety evaluation and dose exploration of SPH3127 tablets in the treatment of mild to moderate ulcerative colitis
以安慰剂为对照,初步评价肾素抑制剂SPH3127片对轻中度溃疡性结肠炎患者的临床有效性,确定推荐剂量。
[Translation] Using placebo as a control, the clinical effectiveness of the renin inhibitor SPH3127 tablets in patients with mild to moderate ulcerative colitis was preliminarily evaluated and the recommended dose was determined.
100 Clinical Results associated with Shanghai Pharmaceutical Group (Benxi) North Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Shanghai Pharmaceutical Group (Benxi) North Pharmaceutical Co., Ltd.
100 Deals associated with Shanghai Pharmaceutical Group (Benxi) North Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Shanghai Pharmaceutical Group (Benxi) North Pharmaceutical Co., Ltd.